Hospital Injectable Products · LP-197
Ondansetron Injection
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-197Hospital Injectable Products
- Generic identity
- OndansetronInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-197
- Generic identity
- Ondansetron
- Presentation
- Injection
- Catalogue strength
- 2 mg/mL
- Catalogue pack
- Ampoule 2 mL / 4 mL; carton 10 ampoules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Ondansetron.
- Dosage form: Injection.
- Catalogue strength / concentration: 2 mg/mL.
- Catalogue pack: Ampoule 2 mL / 4 mL; carton 10 ampoules.
- Catalogue category: Hospital Injectable Products; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Sterile formulation, exact route(s), ampoule/closure specification and whether both volumes are controlled SKUs.
- Dilution/compatibility, administration rate and exact cardiac/QT/interaction warnings for the intended jurisdiction.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 2 mg/mL | Injection | — | Ampoule 2 mL; carton 10 ampoules | Do not infer route, dilution, rate or interchangeability from concentration/volume alone. |
| B | 2 mg/mL | Injection | — | Ampoule 4 mL; carton 10 ampoules | Do not infer route, dilution, rate or interchangeability from concentration/volume alone. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Ondansetron is a serotonin 5-HT3 receptor antagonist used for selected nausea and vomiting indications. Injectable preparations are used in supervised clinical settings where that route is appropriate. It has a different mechanism and safety profile from dopamine-blocking antiemetics. The medicine does not diagnose the cause of vomiting or replace investigation of persistent or severe symptoms.
Clinical context and therapeutic role
Chemotherapy- and surgery-related nausea and vomiting are common contexts described in external medicine information. Selection depends on the emetic risk, other treatments and the patient’s medical history. A catalogue ampoule strength does not define an antiemetic protocol or prove paediatric or pregnancy-related eligibility. General references are provided for education and should be matched to the precise product, route and locally approved information before clinical use.
Selected safety context
QT-interval prolongation and serious arrhythmia are important concerns, especially with relevant cardiac disease, electrolyte disturbances or interacting medicines. Serotonin syndrome can occur with serotonergic combinations. Severe allergy, constipation and headache are additional considerations. Review congenital long-QT syndrome, concurrent apomorphine and medicines that affect cardiac rhythm. Palpitations, fainting, severe allergic symptoms or a serotonin-syndrome pattern require urgent assessment.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The source lists a 2 mg/mL injection in two ampoule volumes. Verify total amount per ampoule, salt, excipients and authorized routes. Oral and injectable formulations need separate instructions; compatibility and dilution cannot be inferred from concentration alone.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Review the antiemetic indication, cardiac and electrolyte risks, interactions and organ function. Confirm the exact ampoule and monitoring requirements under local guidance.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: Ondansetron — ingredient/formulation referenceArchived source classification: government-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-197.
Professional enquiries
Request product-specific evidence for LP-197.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.